Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

On his YouTube channel, "Destino Tolk," the Dominican influencer shared with his colleague Fernan the details of the incident, clarifying that what was initially supposed to be a polyp removal turned ...

In April, she’d begun to use a topical nasal-spray decongestant. The over-the-counter (OTC) drug worked like a charm. By summer, she was still using the spray daily. Yet it was helping for ...

Do any of these symptoms sound familiar: Stuff or Runny Nose? Headaches? Sinus Pressure? Snoring? Many of you probably recognize all of them. But, did you realize any attempt to self-medicate will ...

The study's co-primary endpoints were to see the change from baseline in total endoscopic nasal polyp score at 52 weeks and the change from baseline in mean nasal obstruction score from weeks 49 ...

Those struggles would end, however, if all her future vaccinations could be delivered by a nasal spray. “Oh, my God, amazing!” Velasquez says. If you're enjoying this article, consider ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.